ESMO 2023 Breast Cancer Highlights from Community Oncology
In discussion with Dr. Erika Hamilton, covering the ESMO 2023 Breast Cancer Highlights from Community Oncology perspective.
August 24, 2024
Key Points
Keynote 756 – phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early stage, ER+/HER2- breast cancer, with better pCR seen in pembrolizumab arm
TROPION-Breast01 – Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer, with better PFS and ORR favoring Dato-DXd
Keynote 522 – Event Free Survival update with neoadjuvant and adjuvant pembrolizumab in TNBC, continue to show benefit
Tags:
Related Posts
ConferencesWCLC2025ArticlesSeptember 18, 2025
WCLC 2025 Highlights: FLAURA2, HARMONi, ALCHEMIST with Dr. Balazs Halmos
ConferencesASCO2025July 31, 2025